Document is current
Any future updates will be listed below
-
Authors
Shang, Pei
Ho, Ada Man-Choi https://orcid.org/0000-0003-4989-8782
Tufvesson-Alm, Maximilian
Lindberg, Daniel R.
Grant, Caroline W.
Orhan, Funda
Eren, Feride https://orcid.org/0000-0001-6068-5329
Bhat, Maria
Engberg, Göran https://orcid.org/0000-0003-1659-5232
Schwieler, Lilly
Fatouros-Bergman, Helena
Imbeault, Sophie
Iverson, Ryan M.
Dasari, Surendra
Piehl, Fredrik https://orcid.org/0000-0001-8329-5219
Cervenka, Simon https://orcid.org/0000-0001-8103-6977
Sellgren, Carl M.
Erhardt, Sophie https://orcid.org/0000-0001-7359-5250
Choi, Doo-Sup https://orcid.org/0000-0002-6796-9938
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (AA017830, AA018779, AA027486)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism
U.S. Department of Health & Human Services | NIH | National Institute on Aging (AG072898)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism
- License Information
-
More Information
Article History
Received: 26 April 2022
Revised: 18 May 2022
Accepted: 26 May 2022
First Online: 3 June 2022
Competing interests
: DSC is a scientific advisory board member of Peptron Inc. Peptron had no role in the preparation, review, or approval of the manuscript. SC has served as a speaker for Otsuka Pharmaceuticals and has received grants from AstraZeneca as co-PI. CMS serves as a scientific advisor for Outermost Therapeutics Inc. SE discloses grant support from AstraZeneca and Jansen Pharmaceuticals as principal investigator and has been a speaker for Roche Pharmaceuticals, AstraZeneca, Eli Lilly, Orion Corporation Orion Pharma, and Bristol Myers Squibb (none of these are relevant to this work). All other authors declare no biomedical financial interests or potential conflicts of interest.
